»ï¼ºÃ¢¿øº´¿ø 2020 Samsung Changwon Gynecologic Oncology Expert Meeting : 2020-01-11±³À°ÀÏÀÚ : 2020-01-11
±³À°Àå¼Ò : »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀǽÇ
±³À°ÁÖÁ¦ :
2020 Samsung Changwon Gynecologic Oncology Expert MeetingÁÖÃÖ±â°ü : »ï¼ºÃ¢¿øº´¿ø
´ã´çÀÚ : ±è¹Î±Ô
¿¬¶ôó : 055-233-5922
À̸ÞÀÏ :
minkyu72.kim@samsung.com ±³À°Á¾·ù : »êºÎÀΰú
Âü¼®¿¹»óÀοø : 50¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
°æ»ó³²µµ±³À°½Ã°£ : 6 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 90,000¿ø
ºñ°í »çÀüµî·Ï: 70,000 ÇöÀåµî·Ï:90,000
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 01-11 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 11:50~11:55 Registration ()
±âŸ 01-11 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 11:55~12:00 Opening Remark ±è¹Î±Ô(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 01-11 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 12:00~12:20 Dawn of Personalized Medicine : Genetics ÃÖ¼±½É(°¿ø´ë)
±³À°½Ã°£ 01-11 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 12:20~12:40 Surviving gene,Declining gene : Lesson TCGA (the Cancer Genome Atlas) À̼®¿µ(¿ø±¤ÀÇ´ë)
±³À°½Ã°£ 01-11 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 12:40~13:00 Homologous recombination pathway genes ÀÓ¸íö(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 01-11 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 13:00~13:20 Ideal management for unaffected germline mutation carrier ³²ÀºÁö(¿¬¼¼ÀÇ´ë)
Åä·Ð 01-11 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 13:20~13:25 Discussion ¹Úö¹Î(Á¦ÁÖÀÇ´ë)
±âŸ 01-11 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 13:25~13:30 Q & A ()
±³À°½Ã°£ 01-11 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 13:30~13:50 Advanced Ovary Cancer : Front line ¼Û¿ëÁß(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 01-11 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 13:50~14:10 Platinum-sensitive Recur Ovary Cancer ÃÖöÈÆ(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 01-11 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 14:10~14:30 Platinum-resistant Recur & Persistent Ovary Cancer ÀÌ»êÈñ(¿¬¼¼¿øÁÖÀÇ´ë)
±âŸ 01-11 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 14:30~14:35 Q & A ()
ÈÞ½Ä 01-11 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 14:35~14:40 Coffee Break ()
±³À°½Ã°£ 01-11 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 14:40~15:00 Immune microenvironment and PDL-1 À̾ƿø(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 01-11 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 15:00~15:20 HRD scoring system ¼ºÃ¢¿Á(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 01-11 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 15:20~15:40 MLPA & Liquid bx Á¶ÀºÇØ(³ì½ÊÀÚ Genome)
±³À°½Ã°£ 01-11 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 15:40~16:00 Emerging Target & Tx :Microbiome in Cancer À±°æ¿ø(Áö³ð¿£ÄÄÆÛ´Ï)
Åä·Ð 01-11 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 16:00~16:05 Discussion ()
±âŸ 01-11 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 16:05~16:10 Q & A ()
±³À°½Ã°£ 01-11 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 16:10~16:30 Vaccination in Cancer Patients Á¤´ÙÀº(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 01-11 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 16:30~16:50 Bone Marrow Suppression Treatment and Prophylaxis during Chemotherapy À¯ÇåÁ¾(Ãæ³²ÀÇ´ë)
±³À°½Ã°£ 01-11 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 16:50~17:10 Liver problem and Gynecologic Cancer °û±Ý¿¬(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 01-11 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 17:10~17:30 Specific Value Consideration about Human Genomics: ELSI ÀåÀ±Á¤(±¹¸³¾Ï¼¾ÅÍ)
Åä·Ð 01-11 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 17:30~17:35 Discussant ±è¹Ì¼±(Â÷ÀÇ´ë)
ÈÞ½Ä 01-11 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 17:35~17:40 Coffee Break ()
±³À°½Ã°£ 01-11 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 17:40~18:00 Accurate scaling for Performance status ÀÌÀ¯¿µ(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 01-11 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 18:00~18:20 How to and participate promising clinical trial ÀÌÁ¤À±(¿¬¼¼ÀÇ´ë)
Åä·Ð 01-11 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 18:20~18:25 Discussion ()
±âŸ 01-11 »ï¼ºÃ¢¿øº´¿ø ÇàÁ¤µ¿ 1Ãþ ´ëȸÀÇ½Ç 18:25~18:30 Closing Remark ()